DOCSLIB.ORG

A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abaloparatide abaloparatidum abaloparatidi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abecomotide abecomotidum abekomotidi abediterol abediterolum abediteroli abemaciclib abemaciclibum abemasiklibi abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani abituzumab abituzumabum abitutsumabi ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acalabrutinib acalabrutinibum akalabrutinibi acalisib acalisibum akalisibi acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebilustat acebilustatum asebilustaatti acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic acid acidum aceneuramicum aseneuramiinihappo acenocoumarol acenocoumarolum asenokumaroli aceperone aceperonum aseperoni acepromazine acepromazinum asepromatsiini aceprometazine aceprometazinum aseprometatsiini acequinoline acequinolinum asekinoliini acesulfame acesulfamum asesulfaami acetaminosalol acetaminosalolum asetaminosaloli acetarsol acetarsolum asetarsoli acetazolamide acetazolamidum asetatsolamidi acetergamine acetergaminum asetergamiini acetiamine acetiaminum asetiamiini acetiromate acetiromatum asetiromaatti acetohexamide acetohexamidum asetoheksamidi acetohydroxamic acid acidum acetohydroxamicum asetohydroksaamihappo acetophenazine acetophenazinum asetofenatsiini acetryptine acetryptinum asetryptiini acetylcholine chloride acetylcholini chloridum asetyylikoliinikloridi acetylcysteine acetylcysteinum asetyylikysteiini acetyldigitoxin acetyldigitoxinum asetyylidigitoksiini acetylleucine acetylleucinum asetyylileusiini acetylmethadol acetylmethadolum asetyylimetadoli acevaltrate acevaltratum asevaltraatti acexamic acid acidum acexamicum aseksaamihappo aciclovir aciclovirum asikloviiri acifran acifranum asifraani acipimox acipimoxum asipimoksi acitazanolast acitazanolastum asitatsanolasti acitemate acitematum asitemaatti acitretin acitretinum asitretiini acivicin acivicinum asivisiini aclantate aclantatum aklantaatti aclarubicin aclarubicinum aklarubisiini aclatonium napadisilate aclatonii napadisilas aklatoniumnapadisilaatti aclerastide aclerastidum aklerastidi aclidinium bromide aclidinii bromidum aklidiniumbromidi acodazole acodazolum akodatsoli acolbifene acolbifenum akolbifeeni aconiazide aconiazidum akoniatsidi acorafloxacin acorafloxacinum akorafloksasiini acotiamide acotiamidum akotiamidi acoxatrine acoxatrinum akoksatriini acreozast acreozastum akreotsasti acridorex acridorexum akridoreksi acriflavinium chloride acriflavinii chloridum akriflaviniumkloridi acrihellin acrihellinum akrihelliini acrisorcin acrisorcinum akrisorsiini acrivastine acrivastinum akrivastiini acrocinonide acrocinonidum akrosinonidi acronine acroninum akroniini actagardin actagardinum aktagardiini actaplanin actaplaninum aktaplaniini actarit actaritum aktariitti actinoquinol actinoquinolum aktinokinoli actisomide actisomidum aktisomidi actodigin actodiginum aktodigiini actoxumab actoxumabum aktoksumabi acumapimod acumapimodum akumapimodi adafenoxate adafenoxatum adafenoksaatti adalimumab adalimumabum adalimumabi adamexine adamexinum adameksiini adapalene adapalenum adapaleeni adaprolol adaprololum adaprololi adargileukin alfa adargileukinum alfa adargileukiini alfa adarotene adarotenum adaroteeni adatanserin adatanserinum adatanseriini adecatumumab adecatumumabum adekatumumabi adefovir adefovirum adefoviiri adegramotide adegramotidum adegramotidi adekalant adekalantum adekalantti adelmidrol adelmidrolum adelmidroli ademetionine ademetioninum ademetioniini adenosine phosphate adenosini phosphas adenosiinifosfaatti aderbasib aderbasibum aderbasibi adibendan adibendanum adibendaani adicillin adicillinum adisilliini adinazolam adinazolamum adinatsolaami adiphenine adipheninum adifeniini adipiodone adipiodonum adipiodoni adipiplon adipiplonum adipiploni aditeren aditerenum aditereeni aditoprim aditoprimum aditopriimi adomeglivant adomeglivantum adomeglivantti adomiparin sodium adomiparinum natricum adomipariininatrium adoprazine adoprazinum adopratsiini adosopine adosopinum adosopiini adozelesin adozelesinum adotselesiini adrafinil adrafinilum adrafiniili adrogolide adrogolidum adrogolidi aducanumab aducanumabum adukanumabi afabicin afabicinum afabisiini afacifenacin afacifenacinum afasifenasiini afalanine afalaninum afalaniini afamelanotide afamelanotidum afamelanotidi afasevikumab afasevikumabum afasevikumabi afatinib afatinibum afatinibi afegostat afegostatum afegostaatti afeletecan afeletecanum afeletekaani afelimomab afelimomabum afelimomabi afimoxifene afimoxifenum afimoksifeeni aflibercept afliberceptum aflibersepti afloqualone afloqualonum aflokvaloni afovirsen afovirsenum afovirseeni afoxolaner afoxolanerum afoksolaneeri aftobetin aftobetinum aftobetiini afuresertib afuresertibum afuresertibi afurolol afurololum afurololi agalsidase alfa agalsidasum alfa agalsidaasi alfa agalsidase beta agalsidasum beta agalsidaasi beeta aganepag aganepagum aganepagi aganirsen aganirsenum aganirseeni aganodine aganodinum aganodiini agatolimod agatolimodum agatolimodi aglatimagene besadenovec aglatimagenum besadenovecum aglatimageenibesadenoveekki aglepristone aglepristonum aglepristoni agomelatine agomelatinum agomelatiini aklomide aklomidum aklomidi alacepril alaceprilum alasepriili alacizumab pegol alacizumabum pegolum alasitsumabipegoli aladorian aladorianum aladoriaani alafosfalin alafosfalinum alafosfaliini alagebrium chloride alagebrium chloridum alagebriumkloridi alalevonadifloxacin alalevonadifloxacinum alalevonadifloksasiini alamifovir alamifovirum alamifoviiri alanine alaninum alaniini alanosine alanosinum alanosiini alaproclate alaproclatum alaproklaatti alatrofloxacin alatrofloxacinum alatrofloksasiini alazanine triclofenate alazanini triclofenas alatsaniinitriklofenaatti albaconazole albaconazolum albakonatsoli albenatide albenatidum albenatidi albendazole albendazolum albendatsoli albendazole oxide albendazolum oxidum albendatsolioksidi albifylline albifyllinum albifylliini albiglutide albiglutidum albiglutidi albinterferon alfa-2b albinterferonum alfa-2b albinterferoni alfa-2b albitiazolium bromide albitiazolii bromidum albitiatsoliumbromidi albusomatropin albusomatropinum albusomatropiini albutoin albutoinum albutoiini albutrepenonacog alfa albutrepenonacogum alfa albutrepenonakogi alfa alcaftadine alcaftadinum alkaftadiini alclofenac alclofenacum alklofenaakki alclometasone alclometasonum alklometasoni alcloxa alcloxum alkloksa alcuronium chloride alcuronii chloridum alkuroniumkloridi aldesleukin aldesleukinum aldesleukiini aldesulfone sodium aldesulfonum natricum aldesulfoninatrium aldioxa aldioxum aldioksa aldosterone aldosteronum aldosteroni aldoxorubicin aldoxorubicinum aldoksorubisiini alectinib alectinibum alektinibi alefacept alefaceptum alefasepti aleglitazar aleglitazarum aleglitatsaari alemcinal alemcinalum alemsinaali alemtuzumab alemtuzumabum alemtutsumabi alendronic acid acidum alendronicum alendronihappo alentemol alentemolum alentemoli aleplasinin aleplasininum aleplasiniini alepride alepridum alepridi alestramustine alestramustinum alestramustiini alexidine alexidinum aleksidiini alexitol sodium alexitolum natricum aleksitolinatrium alfacalcidol alfacalcidolum alfakalsidoli alfadex alfadexum alfadeksi alfadolone alfadolonum alfadoloni alfaprostol alfaprostolum alfaprostoli alfatradiol alfatradiolum alfatradioli alfaxalone alfaxalonum alfaksaloni alfentanil alfentanilum alfentaniili alferminogene tadenovec alferminogenum tadenovecum alferminogeenitadenoveekki alfimeprase alfimeprasum alfimepraasi alfuzosin alfuzosinum alfutsosiini algestone algestonum algestoni alglucerase alglucerasum algluseraasi alglucosidase alfa alglucosidasum alfa alglukosidaasi alfa alibendol alibendolum alibendoli alicaforsen alicaforsenum alikaforseeni alicapistat alicapistatum alikapistaatti alicdamotide alicdamotidum alikdamotidi aliconazole aliconazolum alikonatsoli alidornase alfa alidornasum alfa alidornaasi alfa alifedrine alifedrinum alifedriini aliflurane alifluranum alifluraani alilusem alilusemum aliluseemi alimadol alimadolum alimadoli alimemazine alimemazinum alimematsiini alinidine alinidinum alinidiini alipamide alipamidum alipamidi alipogene tiparvovec alipogenum tiparvovecum alipogeenitiparvoveekki alirocumab alirocumabum alirokumabi alisertib alisertibum alisertibi aliskiren aliskirenum aliskireeni alisporivir alisporivirum
Load more

Recommended publications
  • Inclusion and Exclusion Criteria for Each Key Question
    Supplemental Table 1: Inclusion and exclusion criteria for each key question Chronic HBV infection in adults ≥ 18 year old (detectable HBsAg in serum for >6 months) Definition of disease Q1 Q2 Q3 Q4 Q5 Q6 Q7 HBV HBV infection with infection and persistent compensated Immunoactive Immunotolerant Seroconverted HBeAg HBV mono-infected viral load cirrhosis with Population chronic HBV chronic HBV from HBeAg to negative population under low level infection infection anti-HBe entecavir or viremia tenofovir (<2000 treatment IU/ml) Adding 2nd Stopped antiviral therapy antiviral drug Interventions and Entecavir compared Antiviral Antiviral therapy compared to continued compared to comparisons to tenofovir therapy therapy continued monotherapy Q1-2: Clinical outcomes: Cirrhosis, decompensated liver disease, HCC and death Intermediate outcomes (if evidence on clinical outcomes is limited or unavailable): HBsAg loss, HBeAg seroconversion and Outcomes HBeAg loss Q3-4: Cirrhosis, decompensated liver disease, HCC, relapse (viral and clinical) and HBsAg loss Q5: Renal function, hypophosphatemia and bone density Q6: Resistance, flare/decompensation and HBeAg loss Q7: Clinical outcomes: Cirrhosis, decompensated liver disease, HCC and death Study design RCT and controlled observational studies Acute HBV infection, children and pregnant women, HIV (+), HCV (+) or HDV (+) persons or other special populations Exclusions such as hemodialysis, transplant, and treatment failure populations. Co treatment with steroids and uncontrolled studies. Supplemental Table 2: Detailed Search Strategy: Ovid Database(s): Embase 1988 to 2014 Week 37, Ovid MEDLINE(R) In-Process & Other Non- Indexed Citations and Ovid MEDLINE(R) 1946 to Present, EBM Reviews - Cochrane Central Register of Controlled Trials August 2014, EBM Reviews - Cochrane Database of Systematic Reviews 2005 to July 2014 Search Strategy: # Searches Results 1 exp Hepatitis B/dt 26410 ("hepatitis B" or "serum hepatitis" or "hippie hepatitis" or "injection hepatitis" or 2 178548 "hepatitis type B").mp.
    [Show full text]
  • Hyperaldosteronism: How Current Concepts Are Transforming the Diagnostic and Therapeutic Paradigm
    Kidney360 Publish Ahead of Print, published on July 23, 2020 as doi:10.34067/KID.0000922020 Hyperaldosteronism: How Current Concepts Are Transforming the Diagnostic and Therapeutic Paradigm Michael R Lattanzio(1), Matthew R Weir(2) (1) Division of Nephrology, Department of Medicine, The Chester County Hospital/University of Pennsylvania Health System (2) Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD Correspondence: Matthew R Weir University of Maryland Medical Center Division of Nephrology 22 S. Greene St. Room N3W143 Baltimore, Maryland 21201 [email protected] 1 Copyright 2020 by American Society of Nephrology. Abbreviations PA=Primary Hyperaldosteronism CVD=Cardiovascular Disease PAPY=Primary Aldosteronism Prevalence in Hypertension APA=Aldosterone-Producing Adenoma BAH=Bilateral Adrenal Hyperplasia ARR=Aldosterone Renin Ratio AF=Atrial Fibrillation OSA=Obstructive Sleep Apnea OR=Odds Ratio AHI=Apnea Hypopnea Index ABP=Ambulatory Blood Pressure AVS=Adrenal Vein Sampling CT=Computerized Tomography MRI=Magnetic Resonance Imaging SIT=Sodium Infusion Test FST=Fludrocortisone Suppression Test CCT=Captopril Challenge Test PAC=Plasma Aldosterone Concentration PRA=Plasma Renin Activity MRA=Mineralocorticoid Receptor Antagonist MR=Mineralocorticoid Receptor 2 Abstract Nearly seven decades have elapsed since the clinical and biochemical features of Primary Hyperaldosteronism (PA) were described by Conn. PA is now widely recognized as the most common form of secondary hypertension. PA has a strong correlation with cardiovascular disease and failure to recognize and/or properly diagnose this condition has profound health consequences. With proper identification and management, PA has the potential to be surgically cured in a proportion of affected individuals. The diagnostic pursuit for PA is not a simplistic endeavor, particularly since an enhanced understanding of the disease process is continually redefining the diagnostic and treatment algorithm.
    [Show full text]
  • WO 2015/028850 Al 5 March 2015 (05.03.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/028850 Al 5 March 2015 (05.03.2015) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C07D 519/00 (2006.01) A61P 39/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, C07D 487/04 (2006.01) A61P 35/00 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 31/5517 (2006.01) A61P 37/00 (2006.01) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, A61K 47/48 (2006.01) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (21) International Application Number: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, PCT/IB2013/058229 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (22) International Filing Date: TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 2 September 2013 (02.09.2013) ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant: HANGZHOU DAC BIOTECH CO., LTD UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, [US/CN]; Room B2001-B2019, Building 2, No 452 Sixth TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Street, Hangzhou Economy Development Area, Hangzhou EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, City, Zhejiang 310018 (CN).
    [Show full text]
  • Phage Display-Based Strategies for Cloning and Optimization of Monoclonal Antibodies Directed Against Human Pathogens
    Int. J. Mol. Sci. 2012, 13, 8273-8292; doi:10.3390/ijms13078273 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Review Phage Display-based Strategies for Cloning and Optimization of Monoclonal Antibodies Directed against Human Pathogens Nicola Clementi *,†, Nicasio Mancini †, Laura Solforosi, Matteo Castelli, Massimo Clementi and Roberto Burioni Microbiology and Virology Unit, “Vita-Salute” San Raffaele University, Milan 20132, Italy; E-Mails: [email protected] (N.M.); [email protected] (L.S.); [email protected] (M.C.); [email protected] (M.C.); [email protected] (R.B.) † These authors contributed equally to this work. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +39-2-2643-5082; Fax: +39-2-2643-4288. Received: 16 March 2012; in revised form: 25 June 2012 / Accepted: 27 June 2012 / Published: 4 July 2012 Abstract: In the last two decades, several phage display-selected monoclonal antibodies (mAbs) have been described in the literature and a few of them have managed to reach the clinics. Among these, the anti-respiratory syncytial virus (RSV) Palivizumab, a phage-display optimized mAb, is the only marketed mAb directed against microbial pathogens. Palivizumab is a clear example of the importance of choosing the most appropriate strategy when selecting or optimizing an anti-infectious mAb. From this perspective, the extreme versatility of phage-display technology makes it a useful tool when setting up different strategies for the selection of mAbs directed against human pathogens, especially when their possible clinical use is considered.
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A01N 43/00 (2006.01) A61K 31/33 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US2016/028383 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 20 April 2016 (20.04.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/154,426 29 April 2015 (29.04.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: KARDIATONOS, INC. [US/US]; 4909 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Lapeer Road, Metamora, Michigan 48455 (US).
    [Show full text]
  • Mineralocorticoid Receptor Blockers for Moderate Kidney Dysfunction: More Merit Than Ever?
    Hypertension Research (2021) 44:1352–1354 https://doi.org/10.1038/s41440-021-00690-6 COMMENT Mineralocorticoid receptor blockers for moderate kidney dysfunction: more merit than ever? 1 1 1 Masashi Mukoyama ● Takashige Kuwabara ● Masataka Adachi Received: 28 May 2021 / Accepted: 31 May 2021 / Published online: 15 July 2021 © The Japanese Society of Hypertension 2021 Mineralocorticoid receptor (MR) antagonists, such as spir- MR activity with high specificity. To date, several clinical onolactone and eplerenone, are currently used to treat studies have been performed to evaluate its effects [4–6], hypertension and chronic heart failure. MR antagonists act which revealed effective blood pressure reduction with rela- on MRs expressed in the distal tubules of the kidney, tively few adverse events, including hyperkalemia (Table 1). including distal convoluted tubules, connecting tubules and In addition, esaxerenone can further reduce urinary albumin the cortical collecting duct, thereby promoting sodium excretion in addition to RAS inhibitors without significantly excretion without the loss of potassium into the urine [1]. affecting renal function [6]. Finerenone, a second nonsteroidal MR antagonists may be effective for the treatment of low- MR blocker for which large-scale clinical trials have been 1234567890();,: 1234567890();,: renin hypertension and are preferentially used for the completed [7, 8], showed a lower risk of CKD progression treatment of primary aldosteronism; furthermore, in patients and cardiovascular events than placebo in patients with CKD with resistant hypertension, additional administration at a and type 2 diabetes (Table 1). Based on these results, much low to moderate dose (spironolactone, 25–50 mg/day) may attention has been given to novel MR blockers as promising further decrease blood pressure [2].
    [Show full text]
  • The Role of Aldosterone Inhibitors on Cardiac Ischemia/Reperfusion Injury
    Canadian Journal of Physiology and Pharmacology THE ROLE OF ALDOSTERONE INHIBITORS ON CARDIAC ISCHEMIA/REPERFUSION INJURY Journal: Canadian Journal of Physiology and Pharmacology Manuscript ID cjpp-2020-0276.R1 Manuscript Type: Review Date Submitted by the 16-Jul-2020 Author: Complete List of Authors: Dragasevic, Nevena; University of Kragujevac, Faculty of Medical Sciences, Department of Physiology, Svetozara Markovica 69, 34 000 Kragujevac, Serbia JAKOVLJEVIC, Vladimir; University of Kragujevac, Faculty of Medical Sciences, DepartmentDraft of Physiology, Svetozara Markovica 69, 34 000 Kragujevac, Serbia, Department of Physiology; 1st Moscow State Medical University IM Sechenov, Moscow, Russian Federation, Department of Human Pathology Zivkovic, Vladimir; University of Kragujevac, Faculty of Medical Sciences, Department of Physiology, Svetozara Markovica 69, 34 000 Kragujevac, Serbia Draginic, Nevena; University of Kragujevac, Faculty of Medical Sciences, Department of Pharmacy, Svetozara Markovica 69, 34 000 Kragujevac, Serbia Andjic, Marijana; University of Kragujevac, Faculty of Medical Sciences, Department of Pharmacy, Svetozara Markovica 69, 34 000 Kragujevac, Serbia Bolevich, Sergey; University IM Sechenov, 1st Moscow State Medical,Trubetskaya street 8, 119991 Moscow, Department of Human Pathology Jovic, Slavoljub; University of Belgrade, Department of Physiology and Biochemistry, Faculty of Veterinary Medicine, Bul. Oslobodjenja 18, Belgrade, Serbia Is the invited manuscript for consideration in a Special Joint North American/European
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    INN Working Document 05.179 Update 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int ) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • INN Working Document 05.179 Update 2011
    INN Working Document 05.179 Update 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Essential Medicines and Pharmaceutical Policies (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]